Allogene Therapeutics, Inc. (ALLO) Social Stream



Allogene Therapeutics, Inc. (ALLO): $11.76

0.25 (+2.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Allogene Therapeutics Inc (ALLO) Price Targets From Analysts

Use the tables below to see what analysts covering Allogene Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-12-15 14 $45 $18 $33.833 $9.11 271.38%
2021-12-22 14 $43 $18 $32.583 $9.11 257.66%
2022-01-11 14 $43 $14 $32.666 $9.11 258.57%
2022-02-04 14 $43 $14 $31.75 $9.11 248.52%
2022-02-24 14 $43 $14 $30.666 $9.11 236.62%
2022-03-04 13 $43 $14 $29.916 $9.11 228.39%
2022-03-09 13 $43 $14 $29.75 $9.11 226.56%
2022-03-22 13 $43 $14 $29 $9.11 218.33%

The Trend in the Analyst Price Target


ALLO's average price target has moved down $20.23 over the prior 15 months.

Over the past 50 weeks, ALLO's average upside potential has been 121.59%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-22 16 71 37 49.770 26.02 91.28%
2021-07-06 16 71 37 50.140 24.91 101.28%
2021-08-01 16 71 37 50.140 21.95 128.43%
2021-08-14 16 71 37 48.570 21.44 126.54%
2021-12-22 14 43 18 32.583 15.51 110.08%

ALLO Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.46 9 2 2 0 0 13

The Trend in the Broker Recommendations


Over the past 26 weeks, ALLO's average broker recommendation rating improved by 0.25.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • Allogene Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 901.27% of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, Allogene Therapeutics Inc's variance in analysts' estimates is lower than -792.77% of them.
  • Allogene Therapeutics Inc's number of analysts covering the stock is greater than 957.86% of stocks in the mid market cap category.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, Allogene Therapeutics Inc's average analyst price target is greater than 370.02% of them.

In the Pharmaceutical Products industry, AERI, ADGI, and ABCM are the three stocks most similar to Allogene Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is ALLO a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4493 seconds.